January 13, 2026 a 06:00 pm
CRL: Fundamental Ratio Analysis - Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. operates in the healthcare sector, providing vital services for drug discovery and safety testing. Its growth has been consistent, given its diverse segments covering Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. Despite some challenges in its financial metrics, CRL remains a significant player in its industry.
Fundamental Rating
Charles River Laboratories holds a C rating, indicating moderate performance. Here's a breakdown of its fundamental scores:
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 1 | |
| Return on Assets | 1 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 3 |
Historical Rating
The historical trends show a stable current position compared to previous data:
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-01-13 | 2 | 4 | 1 | 1 | 1 | 1 | 3 |
| Previous | 0 | 4 | 1 | 1 | 1 | 1 | 3 |
Analyst Price Targets
Analyst forecasts indicate a positive outlook with various price targets:
| High | Low | Median | Consensus |
|---|---|---|---|
| $260 | $185 | $215 | $214.43 |
Analyst Sentiment
Analysts largely favor this stock, as reflected in the recommendation distribution:
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 24 | |
| Hold | 11 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Charles River Laboratories International, Inc. presents a balanced investment opportunity within the medical research sector. While current metrics reveal some financial challenges, strong analyst confidence suggest prospects for growth. The firm's dedication to drug discovery and non-clinical development maintains its position as a leading contract research organization. Investors should note the potential for improvements in fundamental scores with strategic initiatives. Overall, the stock holds potential for those with a risk-tolerant profile, considering its vital role in healthcare advancements.